R&D The Autumn Budget: What it means for UK life sciences deVere and Inventus comment on the UK Autumn Budget and what it means for life sciences in the country.
R&D Sponsored 12 Questions with Phil Davey Phil Davey is the General Manager at Alnylam for the UK, Ireland, the Nordics, and Canada.
R&D Global pharmaceutical market projections through 2030 Global pharmaceutical market projections through 2030, with Norstella's Daniel Chancellor.
R&D Changing Faces - Pharma and biotech - October 2025 From high-profile resignations to strategic appointments, October was a buzzy month for pharma industry personnel news.
R&D Beyond animal testing: How human data trials are reshaping d... Researchers are beginning to imagine a future in which development pipelines are more predictive, more efficient, and ultimately more humane.
R&D From physics to pharma: How Aqemia is reinventing the future... The UK life sciences sector has long been a crucible for innovation, blending academic excellence with a thriving ecosystem of biotech and pharmaceutical enterprises.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
